Prescription medicine
Acellular tissue engineered vessel Brand names: Symvess
Acellular tissue engineered vessel (Symvess) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
- Boxed warning
Check it at the source: the acellular tissue engineered vessel FDA label on DailyMed (effective December 9, 2025); every acellular tissue engineered vessel label on DailyMed.
Highlights of the record
FDA label of December 9, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
GRAFT FAILURE.
Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage. [See Warnings and Precautions (5.1 , 5.2) ] WARNING: GRAFT FAILURE See full prescribing information for complete boxed warning. Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.
Used for
From the label: indications and usageSYMVESS™ is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.
Forms and strengths
Implant.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 9 through July 30, 2026
What is acellular tissue engineered vessel used for?
From the label: indications and usageSYMVESS™ is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. SYMVESS™ is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.
Source: FDA drug label (Symvess), Humacyte Global, Inc., effective December 9, 2025 (SPL set 15e9e29f-5aa6-4fc6-b0fe-a48cd1473418), via openFDA; the full label on DailyMed
Is there a generic for acellular tissue engineered vessel (Symvess)?
No generic acellular tissue engineered vessel is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the acellular tissue engineered vessel label say about other medicines?
The acellular tissue engineered vessel label names 2 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Aspirin | contraindications | CONTRAINDICATIONS DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries. |
| Clopidogrel | contraindications | CONTRAINDICATIONS DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries. |
Check acellular tissue engineered vessel against other medicines
Source: FDA drug label (Symvess), Humacyte Global, Inc., effective December 9, 2025 (SPL set 15e9e29f-5aa6-4fc6-b0fe-a48cd1473418), via openFDA; the full label on DailyMed
What do FAERS reports show for acellular tissue engineered vessel?
The FDA Adverse Event Reporting System holds 9 reports that list acellular tissue engineered vessel among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1 are coded as a death and 3 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Acellular tissue engineered vessel side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other